Techno Trends

TechnoTrends provide comprehensive coverage of the innovations and inventions in pharma products and pharma technologies across the world. The up-to-date listing of latest pharmaceutical product news and technology trends in the global pharma industry, keeps you abreast with all the latest pharmaceutical innovations happening world over.

Breakthrough Therapy Designation to Adcetris for Frontline Advanced Hodgkin Lymphoma

ADCETRIS brentuximab vedotin in combination with chemotherapy for the frontline treatment of patients with advanced classical Hodgkin lymphoma has been granted breakthrough therapy designation by FDA ADCETRIS is an antibody drug conjugate ADC directed to CD30 a defining marker of classical Hodgki..

Sanofi and Regeneron’s Cemiplimab Receives FDA "Breakthrough Designation"

Sanofi and Regeneron announced that Cemiplimab REGN2810 has received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma Cemiplimab is an investigational human monoclonal antibody targeting PD1 It would be used to treat adults with metastatic cutaneous squamous cel..

New Drug Development Workflow Designed for Extrusion-Based Drug Implant Production

The Thermo Scientific Pharma mini implant line first endtoend solution is an automated integrated system designed for continuous production of drug implants Drug formulation scientists can use the first commercially available fully integrated solution for polymerbased drug implant development and..

Potential Breakthrough Therapy for Cancer based on Pepscan’s CLIPS Technology

Pepscan announced that there is an important progress with a drug development program based on its CLIPS technology Bicycle Therapeutics team in the UK applied Pepscans CLIPS technology to identify a bicyclic CLIPS peptide that selectively binds to a protein MT1MMP present on tumor cells A tox..

World’s First Cell and Gene Therapy for Knee Osteoarthritis Gets Approval

The worlds first cell and gene therapy for knee osteoarthritis InvossaK Inj gets approval from the Korea Ministry of Food and Drug Safety MFDS This therapy was manufactured by Kolon Life Science and it has received exclusive licensee for Asia including Korea Invossa is a firstinclass cellmedia..

New Method for Residual Solvent Characterization by GC-VUV

A new method has been announced by VUV Analytics for residual solvent testing in pharmaceutical products and excipients that significantly reduces analysis time while improving testing throughput It allows the combination of various sample types into a single test The gas chromatography Vacuum U..

FDA grants breakthrough therapy designation to Toca 511 & Toca FC in Recurrent High Grade Glioma

Tocagens new gene therapeutic formulations Toca 511 Toca FC for treating recurrent and metastatic cancers specifically HighGrade Glioma HGG received FDAs breakthrough therapy designation and awaits a full approval post clinical trials next year HGG is a malignant form of primary brain tumour t..

FDA Approves Novartis Kisqali® Femara® Co-Pack to treat metastatic breast cancer

Novartis has announced that its Kisqali Femara CoPack the first and only currently available combination pack with two prescription products in advanced breast cancer has received approval from the US Food and Drug Administration FDA The Kisqali Femara CoPack ribociclib tablets letrozole tablets ..

MagBio Launches its Novel cfKapture 21 Kit

MagBio Genomics announces the launch of its new cfKapture 21 kit cfKapture 21 kit is said to be a novel solution for isolation of circulating CellFree DNA ccfDNA from stabilized plasma sample cfKapture 21 system is a ccfDNA isolation kit which includes a proprietary reagent that prevents postsepa..

Evotec and Eternygen to Develop Novel Metabolic Disease Therapy

Evotec and Eternygen announced a drug discovery collaboration to develop novel metabolic disease therapy The two companies will develop novel small molecule inhibitors against an Eternygen target to treat metabolic disease using Evotecs technology platform and broad expertise in drug discovery an..

TOP